SOURCE: Gene Express, Inc.

November 16, 2007 09:14 ET

Gene Express Appoints Larissa Karnaoukhova Director of Strategic Partnerships

TOLEDO, OH--(Marketwire - November 16, 2007) - Gene Express, Inc. today announced the appointment of Larissa Karnaoukhova, Ph.D. to Director of Strategic Partnerships.

Gerald Vardzel, CEO of Gene Express, commented, "Larissa brings to the Company over 9 years of product development, program management and strategy development within the biotechnology industry. She will be responsible for building relationships with key partners, and managing business development on the West coast. Her extensive experience includes complete sales cycle management of bio-pharmaceutical and diagnostic services, as well as full-cycle product development from feasibility to product launch and technical support. All of this will play an integral role in furthering Gene Express's commercial development."

Prior to joining Gene Express, Dr. Karnaoukhova served as the Biosciences Sales Manager at VWR International, a leading product supplier to the global research laboratory industry. In this role, she was responsible for promoting and selling drug discovery and development services from a broad range of contract research organizations (CROs) to biotech, pharmaceutical and medical device companies in Southern California and Arizona. At VWR International, she succeeded in identifying customer needs, in turn presenting solutions through a diverse portfolio of services in genomics, proteomics, pre-clinical development, scale-up manufacturing, imaging, lab automation instrumentation, and clinical trials. Ultimately, this enabled Ms. Karnaoukhova to design strategies to broaden the customer base.

Over the previous nine years, Dr. Karnaoukhova developed her scientific career at Invitrogen Corporation, where she took on positions of increasing responsibility. She developed innovative products and services in gene identification and cloning, and served most recently as a Senior Scientist, facilitating program management in cloning and protein expression. She has authored several academic and scientific publications, highlighting her expertise in gene isolation, cloning, and gene expression. Dr. Karnaoukhova is currently working towards receiving an MBA from UCSD, RADY School of Management. She received her Ph.D. in Molecular Biology from the University of Victoria, Victoria, British Columbia in 1998, and an M.Sc. in Physics/Biophysics from Moscow State University, Moscow, Russia in 1992.

Dr. Karnaoukhova stated, "I am pleased to join such a prestigious team of professionals at Gene Express. Gene Express's StaRT-PCR™ technology offers a recognized platform for standardizing genomic expression data, which is essential in personalized medicine. I look forward to establishing and growing strategic partnerships in the drug development space in order for our products to gain sustained recognition and ultimate success."

About Gene Express, Inc.

Gene Express, Inc. accelerates and enables drug and molecular diagnostic development by providing standardized genomic data. The Company's proprietary and patented StaRT-PCR™ (Standardized Reverse Transcription Polymerase Chain Reaction) platform technology for measuring gene expression levels in cells, clinical biopsies and blood is being used by numerous pharmaceutical concerns, as well as leading academic centers. The Company's $3 billion focus market for licensing and contract services includes the drug development, academic and molecular diagnostics segments. Additional information is available on the Company's website at www.geneexpressinc.com.

Any forecasts, plans, projections and other information contained in this press release describing events or results that may occur in the future are "forward-looking statements" as defined in the United States Private Securities litigation Reform Act of 1995. Forward-looking statements are subject to risks, uncertainties and important factors that are beyond the control of the Company that could cause actual results and events to differ materially from the results presently anticipated or projected. Readers are cautioned not to place undue reliance on these forward-looking statements and any such forward-looking statements are qualified in their entirety by reference to this cautionary statement. All forward-looking statements contained herein speak only as of the date of this release and are based on current expectations. The Company disclaims any obligation to update or revise any forward-looking statements.

Contact Information